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We modeled temporal trends in the 1- and 5-year survival of 32499 patients with adenocarcinoma and squamous cell carcinoma of
the lung in the Swedish Cancer Register between 1961 and 2000. The 1-year relative survival for adenocarcinoma improved from
37% for patients diagnosed 1961–1965 to 45% for those diagnosed 1996–2000 and from 39 to 45% for squamous cell carcinoma.
The adjusted excess mortality ratios for the period 1996–2000 compared with 1961–1965 were 0.80 for adenocarcinoma and 0.81
for squamous cell carcinoma. Thus, a previous report in a Dutch study of a relatively worsening prognosis for adenocarcinoma over
time could not be confirmed.
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Over the past three decades in many Western countries, there has
been a relative increase in the incidence of adenocarcinoma of the
lung compared with other histological types (Janssen-Heijnen and
Coebergh, 2001; 2003). The same phenomenon has been observed
in Sweden, particularly among men (Myrdal et al, 2001). This shift
cannot be attributed simply to changes in classification or
diagnostic methods (Charloux et al, 1997). It is more likely to
reflect the increased use of lower tar and nicotine cigarettes,
which are suspected of preferably favouring the development of
adenocarcinoma (Wynder and Muscat, 1995; Stellman et al, 1997;
Thun et al, 1997).
Data from a regional population-based cancer register in the
Netherlands during the period 1975–1994 indicated not only
doubling of the relative incidence of adenocarcinoma but also a
decline in its relative survival, even as relative survival ratios
(RSRs) remained unchanged for other forms of non-small cell lung
cancer. It was hypothesised that the decreased survival was also
related to increased use of lower-yield cigarettes, and suggested
that among adenocarcinomas, those caused by smoking may be
more aggressive than those unrelated to smoking (Janssen-Heijnen
et al, 2001).
We used nationwide, population-based data for Sweden over a
40-year period to investigate survival trends for adenocarcinoma
compared with squamous cell carcinoma, the other main type of
non-small cell lung cancer.
METHODS
Data for this analysis were derived from the national Swedish
Cancer Register (SCR), which was established in 1958. Swedish law
mandates the report of all newly diagnosed malignant tumours, as
well as benign tumours from selected sites. The completeness of
reporting to the SCR has been very high throughout its existence;
in 1975, it was estimated that almost 100% of all malignant
tumours were reported (National Board of Health and Welfare,
1980). The SCR uses the ICD-7 to classify primary site and the
PAD code, assigned by the diagnosing pathologist, to denote the
histological subtype. Approximately 97% of the cases are
morphologically verified with little change over time (National
Board of Health and Welfare, 1998).
Criteria for inclusion in this analysis included age
20–80, diagnosis of a malignant lung tumour (ICD-7: 162.1)
between 1961 and 2000 and no prior diagnosis of cancer. Because
large cell carcinoma and small cell lung cancer were combined as
one category until 1985, we limited the analyses to individuals with
the two main types of non-small cell lung cancer: adenocarcinoma
(PAD: 96) and squamous cell carcinoma (PAD: 146). From the
39714 cases originally eligible, we excluded 7215 individuals who
were diagnosed at autopsy or survived less than 1 month after
diagnosis. The final dataset consisted of 32499 patients.
Follow-up for mortality is conducted routinely by the
SCR through linkage with the Cause of Death Register. We
included follow-up for death through the end of 2002 and
calculated 1- and 5-year RSRs by sex and histologic type for
individuals diagnosed during successive 5-year calendar periods
(1961–1965, 1966–1970,y, 1996–2000). The RSR represents the
ratio of observed survival among individuals with lung cancer to
expected survival based on the sex, age (5-year categories) and
period-specific mortality of the general population (Ederer et al,
1961). Data for expected survival were derived from population life
tables.
To study changes in survival over calendar period of diagnosis
for adenocarcinoma and squamous cell carcinoma while adjusting
for age and sex, we modelled the excess mortality (observed minus
expected) using Poisson regression. The excess mortality ratio
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yrepresents the relative excess mortality within each 5-year
calendar period compared with the reference period of
1961–1965 (Dickman et al, 2004). We calculated 95% confidence
intervals for both RSRs and excess mortality ratios. Analyses were
performed using Stata (Dickman et al, 2007). The study was
approved by the Regional Ethics Board of Akademiska Sjukhuset,
Uppsala.
RESULTS
Table 1 provides information on the number of cases of
lung adenocarcinoma and squamous cell carcinoma by sex and
decade. The proportion of all cases occurring among women
doubled from 17% during 1961–1970 to 36% during 1991–2000.
Adenocarcinoma steadily increased from 17% of all cases among
men during 1961–1970 to 41% in 1991–2000. Among women,
adenocarcinoma accounted for 60% of cases during 1961–1990
and increased to 65% during the most recent period under study
(1991–2000).
The 1-year RSR for adenocarcinoma improved from 37% for
diagnoses in 1961–65 to 45% for 1996–2000, and from 38% to
45% for squamous cell carcinoma (Table 2). The corresponding
figures for the 5-year RSR were 14% (1961–1965) to 17% (1996–
2000) for both adenocarcinoma and squamous cell carcinoma.
Although absolute estimates of relative survival decreased in a
separate analysis that included patients dying within 1 month of
diagnosis, the survival patterns remained essentially unchanged
(data not shown). Even over the specific period (1975–1994)
covered by the previous report (Janssen-Heijnen et al, 1998), both
1- and 5-year RSRs remained essentially unchanged in our data for
both histologic groups.
The excess mortality ratios, adjusted for gender and age,
for the period 1996–2000 compared with 1961–1965 were
0.80 for adenocarcinoma and 0.81 for squamous cell carcinoma
(Table 2). For both histologic groups, a substantial fraction
of the improvement occurred during the most recent calendar
period.
DISCUSSION
Over the past 40 years, there has been modest improvement in
1-year and little change in 5-year relative survival for lung
adenocarcinoma and squamous cell carcinoma in Sweden, most of
the improvement being in the last decade, perhaps reflecting more
intensive early detection, the introduction of new cytotoxic
regimens and implementation of guidelines promoting chemother-
apy in advanced disease (American Society of Clinical Oncology,
1997).
Our finding that trends in survival over time were similar for
both cell types did not confirm the earlier observation (Janssen-
Heijnen et al, 1998) of a worsening trend with adenocarcinoma.
Reasons for the different results in our studies are not obvious as
both were based on population-based registers with similar
eligibility criteria and analytical methods. Historically, both
smoking prevalence and lung cancer mortality have been
substantially higher in the Netherlands than Sweden (Statistics
Sweden, 1997; Liaw et al, 2005). Consequently, the proportion of
adenocarcinomas attributable to smoking was probably greater in
the Netherlands, and this may have contributed to the survival
differences. In addition, we cannot rule out differences in
diagnostic, treatment or pathological classification practices
between the two countries.
The increased incidence of adenocarcinoma observed in
Sweden has also occurred on a global scale (Charloux et al, 1997;
Jansssen-Heijnen and Coebergh, 2001). Originally, adenocarcino-
ma was considered to occur primarily among non-smokers (Doll
et al, 1957; Kreyberg, 1961), but later studies demonstrated that it
is also strongly associated with smoking (Thun et al, 1997;
Simonato et al, 2001; Yang et al, 2002). The increased incidence of
adenocarcinoma among smokers may be explained by the
widespread introduction of filter and lower-tar and nicotine
cigarettes (Wynder and Muscat, 1995; Stellman et al, 1997; Thun
et al, 1997).
In 1946, 50% of men and 9% of women in Sweden were daily
smokers (www.tobaksfakta.org/default.aspx?id¼3622). Filter
cigarettes first became available in Sweden during the late
1950s, whereas reduced tar and nicotine cigarettes were
introduced in the early 1970s and now dominate the market.
The substantial increase in adenocarcinoma as a proportion
of all cases among men over the past 40 years is consistent
with early use of non-filter cigarettes followed by a transition to
filter and low-tar cigarettes. Because of their later uptake of
smoking, women were always more likely to smoke filter and low-
tar cigarettes. Adenocarcinoma has always occurred more
frequently than squamous cell carcinoma among women. How-
ever, cases in the earlier period were more likely to be non-
smoking-related, whereas more recent cases are more likely to be
caused by smoking.
Strengths of our study included the nationwide scope, the large
number of cases over a 4-decade period and the high case
ascertainment. Throughout the study period, less than 3% of all
Table 1 Number of lung cancer cases (adenocarcinoma or squamous cell carcinoma only), by calendar period and gender, Swedish Cancer Register,
1961–2000
1961–1970 1971–1980 1981–1990 1991–2000
M F MF M FMF
Overall 4084 (83) 864 (17) 6295 (81) 1451 (19) 6987 (74) 2428 (26) 6605 (64) 3785 (36)
Age at diagnosis
20–40 47 (1) 31 (4) 53 (o1) 30 (2) 77 (1) 64 (3) 40 (o1) 55 (1)
41–50 263 (6) 95 (11) 323 (5) 140 (10) 380 (5) 257 (11) 360 (5) 396 (10)
51–60 1047 (26) 214 (25) 1368 (22) 334 (23) 1275 (18) 523 (22) 1146 (17) 915 (24)
61–70 1843 (45) 288 (33) 2641 (42) 553 (38) 2885 (41) 921 (38) 2559 (39) 1264 (33)
71–80 884 (22) 236 (27) 1910 (30) 394 (27) 2370 (34) 663 (27) 2500 (38) 1155 (31)
Histologic group
Adenocarcinoma 688 (17) 516 (60) 1290 (20) 871 (60) 2153 (31) 1447 (60) 2693 (41) 2473 (65)
Squamous cell carcinoma 3396 (83) 348 (40) 5005 (80) 580 (40) 4834 (69) 981 (40) 3912 (59) 1312 (35)
Percentage within each decade in parentheses.
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information on stage at diagnosis and were unable to evaluate
the trend in the stage distribution by histologic type. Janssen-
Heijnen et al (1998) found that the proportion of cases diagnosed
at a localised stage decreased over the study period for
adenocarcinoma but increased for squamous cell carcinoma. We
also had no information on smoking, which would have permitted
a direct comparison of the survival of persons diagnosed with
adenocarcinoma according to their smoking history. One registry-
based study in Japan with such information found smoking was
associated with poorer survival for adenocarcinoma but not for
other histological types (Kato et al, 1990).
In conclusion, we did not find a worsening trend for survival
for adenocarcinoma of the lung in Sweden over a 40-year
period. Nevertheless, a variety of studies suggests that adenocarci-
noma due to smoking differs from other adenocarcinomas
(Ahrendt et al, 2001; Ishikawa et al, 2002; Miura et al, 2002;
Toyooka et al, 2006). It is too soon to decide whether or not these
differences have implications for patient survival. Additional
studies with information on tobacco use would help determine
whether adenocarcinoma has become more deadly as it has
become more common and more closely associated with cigarette
smoking.
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Table 2 One- and 5-year RSRs and excess mortality ratios with 95% CI over calendar period by gender and histologic group, Swedish Cancer Register,
1961–2000
1961–1965 1966–1970 1971–1975 1976–1980 1981–1985 1986–1990 1991–1995 1996–2000
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
1-year RSR
Overall
Adenocarcinoma 37.0 (32.8–41.3) 32.6 (29.1–36.2) 36.9 (33.8–40.0) 40.0 (37.2–42.8) 38.0 (35.6–40.4) 37.7 (35.5–39.9)39.6 (37.6–41.6) 44.7 (42.8–46.6)
Squamous cell
carcinoma
38.5 (36.1–40.9) 40.3 (38.2–42.5) 40.7 (38.8–42.7) 42.8 (40.9–44.6) 44.2 (42.4–46.0) 41.4 (39.5–43.3)41.6 (39.7–43.4) 45.3 (43.2–47.3)
Male
Adenocarcinoma 32.2 (26.8–37.8) 30.0 (25.5–34.6) 36.5 (32.5–40.5) 36.5 (32.9–40.1) 34.1 (31.1–37.1) 36.6 (33.8–39.4)37.3 (34.6–40.0) 41.7 (39.0–44.3)
Squamous cell
carcinoma
39.0 (36.5–41.5) 40.8 (38.5–43.1) 41.0 (38.9–43.0) 43.3 (41.3–45.2) 45.1 (43.2–47.1) 41.4 (39.3–43.5)41.6 (39.4–43.7) 44.4 (42.0–46.9)
Female
Adenocarcinoma 43.1 (36.5–49.6) 36.1 (30.6–41.7) 37.6 (32.5–42.6) 44.9 (40.5–49.3) 43.9 (40.0–47.8) 39.3 (35.9–42.7)42.1 (39.2–45.0) 47.8 (45.1–50.5)
Squamous cell
carcinoma
33.8 (26.4–41.4) 35.8 (29.0–42.7) 38.0 (31.7–44.3) 38.7 (33.5–43.9) 39.3 (35.0–43.6) 41.3 (36.8–45.7)41.6 (37.7–45.5) 47.3 (43.4–51.1)
5-year RSR
Overall
Adenocarcinoma 13.8 (10.9–17.2) 10.9 (8.6–13.6) 12.9 (10.8–15.3) 13.8 (11.9–16.0) 12.5 (10.9–14.3) 12.9 (11.3–14.5)14.5 (13.0–16.0) 16.7 (15.1–18.4)
Squamous cell
carcinoma
14.2 (12.5–16.1) 13.6 (12.0–15.2) 14.5 (13.0–16.0) 13.9 (12.5–15.2) 13.9 (12.6–15.3) 14.1 (12.7–15.5)14.9 (13.5–16.3) 17.1 (15.3–18.9)
Male
Adenocarcinoma 12.9 (9.1–17.3) 9.3 (6.6–12.6) 13.1 (10.3–16.2) 11.4 (9.0–14.1) 9.9 (8.0–12.1) 12.5 (10.6–14.7)11.3 (9.5–13.2) 13.4 (11.3–15.7)
Squamous cell
carcinoma
14.3 (12.4–16.2) 13.4 (11.8–15.1) 14.8 (13.3–16.4) 14.0 (12.6–15.5) 14.1 (12.7–15.6) 13.9 (12.4–15.5)13.9 (12.4–15.5) 16.9 (14.8–19.1)
Female
Adenocarcinoma 15.1 (10.6–20.4) 13.2 (9.4–17.6) 12.8 (9.5–16.6) 17.3 (14.0–20.9) 16.3 (13.5–19.4) 13.4 (11.0–15.9)17.9 (15.7–20.3) 20.2 (17.7–22.7)
Squamous cell
carcinoma
13.7 (8.6–20.1) 15.2 (10.2–21.0) 11.0 (7.3–15.6) 12.7 (9.3–16.6) 12.9 (10.0–16.2) 14.8 (11.6–18.3)18.1 (15.1–21.4) 17.6 (14.4–21.2)
Excess mortality ratio
Overall
Adenocarcinoma 1 (ref) 1.13 (1.00–1.28) 0.98 (0.87–1.10) 0.91 (0.82–1.02) 0.94 (0.85–1.05) 0.94 (0.85–1.05)0.90 (0.81–1.00) 0.80 (0.72–0.88)
Squamous cell
carcinoma
1 (ref) 0 96 (0.89–1.03) 0.93 (0.87–1.00) 0.90 (0.84–0.96) 0.87 (0.82–0.93) 0.91 (0.85–0.97)0.89 (0.83–0.95) 0.81 (0.76–0.87)
Male
Adenocarcinoma 1 (ref) 1.13 (0.96–1.33) 0.92 (0.79–1.08) 0.93 (0.80–1.08) 0.97 (0.84–1.12) 0.88 (0.77–1.02)0.90 (0.78–1.03) 0.79 (0.69–0.91)
Squamous cell
carcinoma
1 (ref) 0.96 (0.89–1.04) 0.92 (0.86–0.99) 0.90 (0.83–0.96) 0.86 (0.80–0.92) 0.91 (0.84–0.98)0.90 (0.84–0.97) 0.81 (0.75–0.88)
Female
Adenocarcinoma 1 (ref) 1.12 (0.93–1.36) 1.06 (0.88–1.27) 0.89 (0.74–1.06) 0.90 (0.76–1.07) 1.02 (0.87–1.20)0.91 (0.78–1.07) 0.81 (0.69–0.95)
Squamous cell
carcinoma
1 (ref) 0.92 (0.73–1.16) 0.98 (0.79–1.23) 0.90 (0.73–1.11) 0.87 (0.71–1.06) 0.82 (0.67–1.00)0.75 (0.62–0.91) 0.71 (0.58–0.86)
Abbreviations: CI¼confidence interval; RSR¼relative survival ratio. Estimates are conditional on survival at least 1 month and are adjusted for age.
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